The term polyendocrine metabolic ovarian syndrome (PMOS) reframes polycystic ovary syndrome as a multisystem endocrine disorder rather than a condition defined primarily by ovarian morphology. The heterogeneous presentation of PMOS appears to reflect genetic and epigenetic susceptibility interacting with environmental influences and interconnected neuroendocrine, metabolic and ovarian pathways. In addition, the associated insulin resistance and compensatory hyperinsulinaemia amplify ovarian androgen production, while androgen excess, adipose dysfunction and altered gonadotropin signalling can further impair metabolic function, follicular development and ovulation. These reinforcing mechanisms help explain the variable combinations of menstrual disturbance, hirsutism, infertility and metabolic risk seen across the lifespan. This presentation will integrate the metabolic, androgenic and reproductive dimensions of PMOS and consider whether this broader framework can improve clinical assessment and support individualised management of reproductive goals, androgen-related symptoms, weight and long-term cardiometabolic and endometrial health.